Narittee Sukswai1,2, Joseph D Khoury3. 1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Pathology, Chulalongkorn University, Bangkok, Thailand. 3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jkhoury@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Immunohistochemistry is an integral technique for tissue-based diagnostics and biomarker detection with broad worldwide adoption. Advances in core chemistries, antibody design, and automation have ushered unprecedented sensitivity, specificity, and reproducibility in immunohistochemistry assays. As a result, clinical immunohistochemistry assays that utilize dual-color approaches and mutation-specific antibodies provide novel tools in clinical diagnostics that until recently were in the realm of investigational research. This review provides an overview of innovations in clinical immunohistochemistry assays with emphasis on those used for patients with hematopoietic neoplasms. RECENT FINDINGS: Advances in clinical-grade immunohistochemistry techniques have allowed labs to develop and validate multiplex assays that improve diagnostic utility-such as CD5/PAX5 and TCF4/CD123 dual-color stains-and have the potential to enhance the specificity of biomarker detection. In addition, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are relatively cost-effective, making them valuable novel tools in modern cancer care. Multiplex and mutation-specific immunohistochemistry assays represent important innovations that provide improved utility in the context of personalized medicine and targeted therapy.
PURPOSE OF REVIEW: Immunohistochemistry is an integral technique for tissue-based diagnostics and biomarker detection with broad worldwide adoption. Advances in core chemistries, antibody design, and automation have ushered unprecedented sensitivity, specificity, and reproducibility in immunohistochemistry assays. As a result, clinical immunohistochemistry assays that utilize dual-color approaches and mutation-specific antibodies provide novel tools in clinical diagnostics that until recently were in the realm of investigational research. This review provides an overview of innovations in clinical immunohistochemistry assays with emphasis on those used for patients with hematopoietic neoplasms. RECENT FINDINGS: Advances in clinical-grade immunohistochemistry techniques have allowed labs to develop and validate multiplex assays that improve diagnostic utility-such as CD5/PAX5 and TCF4/CD123 dual-color stains-and have the potential to enhance the specificity of biomarker detection. In addition, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAFV600E and IDH1R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are relatively cost-effective, making them valuable novel tools in modern cancer care. Multiplex and mutation-specific immunohistochemistry assays represent important innovations that provide improved utility in the context of personalized medicine and targeted therapy.
Authors: A Pardanani; K K Reichard; D Zblewski; R A Abdelrahman; E A Wassie; W G Morice Ii; C Brooks; K L Grogg; C A Hanson; A Tefferi; D Chen Journal: Leukemia Date: 2015-12-18 Impact factor: 11.528
Authors: Michele Ceribelli; Zhiying Esther Hou; Priscilla N Kelly; Da Wei Huang; George Wright; Karthik Ganapathi; Moses O Evbuomwan; Stefania Pittaluga; Arthur L Shaffer; Guido Marcucci; Stephen J Forman; Wenming Xiao; Rajarshi Guha; Xiaohu Zhang; Marc Ferrer; Laurence Chaperot; Joel Plumas; Elaine S Jaffe; Craig J Thomas; Boris Reizis; Louis M Staudt Journal: Cancer Cell Date: 2016-11-14 Impact factor: 31.743
Authors: Joseph D Khoury; Dan Jones; Marwan A Yared; John T Manning; Lynne V Abruzzo; Fredrick B Hagemeister; L Jeffrey Medeiros Journal: Am J Surg Pathol Date: 2004-04 Impact factor: 6.394
Authors: Neval Ozkaya; Marc K Rosenblum; Benjamin H Durham; Janine D Pichardo; Omar Abdel-Wahab; Meera R Hameed; Klaus J Busam; William D Travis; Eli L Diamond; Ahmet Dogan Journal: Mod Pathol Date: 2017-12-01 Impact factor: 7.842
Authors: Albert Gutierrez; Bonnie K Arendt; Renee C Tschumper; Neil E Kay; Clive S Zent; Diane F Jelinek Journal: PLoS One Date: 2011-10-06 Impact factor: 3.240
Authors: Ifeyinwa E Obiorah; Hao-Wei Wang; David Ma; Eddie Martin; Wyndham H Wilson; Raul Braylan Journal: Am J Clin Pathol Date: 2022-05-04 Impact factor: 5.400
Authors: Icela Palma-Lara; Ana Elena Sánchez-Aldana; Elva Jiménez-Hernández; Octavio Martínez-Villegas; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré; Sara A Ochoa; Juan Xicohtencatl-Cortes; Ariadnna Cruz-Córdova; Sergio Zavala-Vega; Mariana García-Jiménez; Alejandra Contreras-Ramos; José Refugio Torres-Nava; Guillermo Mora-Ramiro; José Arellano-Galindo Journal: Microorganisms Date: 2020-06-26
Authors: Yasmin Alwash; Joseph D Khoury; Mehrnoosh Tashakori; Rashmi Kanagal-Shamanna; Naval Daver; Farhad Ravandi; Tapan M Kadia; Marina Konopleva; Courtney D Dinardo; Ghayas C Issa; Sanam Loghavi; Koichi Takahashi; Elias Jabbour; Veronica Guerra; Steven Kornblau; Hagop Kantarjian; Nicholas J Short Journal: Am J Hematol Date: 2021-08-19 Impact factor: 13.265
Authors: Wen Shuai; Pei Lin; Paolo Strati; Keyur P Patel; Mark J Routbort; Shimin Hu; Peng Wei; Joseph D Khoury; M James You; Sanam Loghavi; Zhenya Tang; Hong Fang; Beenu Thakral; L Jeffrey Medeiros; Wei Wang Journal: Blood Cancer J Date: 2020-08-26 Impact factor: 11.037